Plus our top ESMO coverage

This Week

Oct 27, 2023

Amgen plans to lay off 350 former Horizon employees after $28B buyout


J&J bites back against dengue, linking antiviral to protection from infection in challenge trial


Merck pays $4B upfront for rights to 3 Daiichi ADCs in huge bet on post-Keytruda future


ESMO: Moderna, BioNTech's post-COVID futures in oncology hit manufacturing realities


ESMO: In PD-1 battle GSK waged on Merck, Jemperli appears to show survival edge over Keytruda in lung cancer


ESMO: Novartis' booming Pluvicto posts mixed results in earlier prostate cancer

 

Featured

Amgen plans to lay off 350 former Horizon employees after $28B buyout

In the biopharma industry, post-merger layoffs are often a question of when and how many. In the case of Amgen’s $27.8 billion buyout of Horizon, they came quickly. Around 350 former Horizon employees are being told this week that their positions will be eliminated.
 

Top Stories

J&J bites back against dengue, linking antiviral to protection from infection in challenge trial

One of the last drugs standing at Johnson & Johnson’s slimmed-down infectious disease unit has come through another test. The oral candidate, JNJ-1802, induced antiviral activity against dengue in a human challenge study, offering J&J encouragement as it works toward data in a larger community-based trial.

Merck pays $4B upfront for rights to 3 Daiichi ADCs in huge bet on post-Keytruda future

Merck & Co. has secured a seat at the productive Daiichi Sankyo antibody-drug conjugate (ADC) factory. While AstraZeneca picked up the first two ADCs off the production line, its rival and collaborator Merck is paying $4 billion upfront to co-develop Daiichi’s next three prospects.

ESMO: Moderna, BioNTech's post-COVID futures in oncology hit manufacturing realities

MADRID—Moderna and BioNTech have quite a few things in common, one being that both are trying to chart their post-COVID course by reinventing cancer modalities. And both, it seems, have run into the reality of manufacturing challenges.

ESMO: In PD-1 battle GSK waged on Merck, Jemperli appears to show survival edge over Keytruda in lung cancer

Last year, a first-of-its-kind head-to-head clinical trial between two PD-1 inhibitors went in GSK’s favor. Now, the British pharma has some new patient survival data to celebrate.

ESMO: Novartis' booming Pluvicto posts mixed results in earlier prostate cancer

As Novartis aims to move its radiotherapy Pluvicto into an earlier treatment setting in prostate cancer, it has posted a mixed bag of trial data that cast a cloud of uncertainty over its regulatory path forward.

ESMO: BioNTech's new CAR-T manufacturing process boosts potency … and side effects

BioNTech’s new manufacturing process for CAR-T seems to have done the trick in boosting the potency of the solid tumor therapy BNT211, but that bit of extra juice seems to have upped the side effect profile as well.

ESMO: Searching for the perfect cup of pharma-branded espress-MO in Madrid

If anyone in Spain is wondering where the espresso machines are, they are at the exhibit hall for the European Society for Medical Oncology Congress, where one faces an important question: From which Big Pharma will I accept my complimentary espresso beverage?

Johnson & Johnson MedTech head Ashley McEvoy to leave company after nearly 30 years

After spending the better part of the last three decades at Johnson & Johnson, Ashley McEvoy, worldwide chair of its medtech franchises, is charting a new course.

Move over COVID-19 vaccines. Pan-coronavirus shot proves effective against MERS, SARS and more in mice

A vaccine designed to target three different strains of potentially lethal coronaviruses, including the one that causes COVID-19, appears to be effective in mice.
 
Fierce podcasts

Don’t miss an episode

'Podnosis': Cultivating cultural competency in the healthcare workforce

In this week's episode of “Podnosis,” we look at the major health disparities facing Native Americans and explore what can be done to make meaningful improvements. 
 

Resources

Whitepaper

Improving patient outcomes with point-of-care AI

Is pharma spending money on the wrong types of AI? Here’s how real-time clinical alerts could change the minds of the world’s top commercial leaders.
Whitepaper

Understanding the hidden value of quality

Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development.
Whitepaper

What Are the Benefits of Generative AI for Pharma?

From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level.
Whitepaper

The transformative role of pDNA in Cell and Gene therapy

Want to know the Top 5 criteria for selecting the ‘right’ CDMO for pDNA manufacturing?
eBook

Improving yield and reproducibility with advanced sample prep

Learn how to get better results from suboptimal biospecimens for NGS and protein analysis.
Whitepaper

Tailored and Targeted Pharmaceutical Marketing at Scale

Learn more about targeted personas for HCP marketing.
eBook

Single-cell Sequencing in Drug Development

Learn how single-cell sequencing speeds up drug development and delivers valuable biological insights.

eBook

An Introduction to Organ-on-a-Chip Technology

Emulate in vivo biology with next-generation in vitro technology.
Whitepaper

Accelerate drug discovery with high-performance computing powered by the cloud

Accelerate drug discovery with high-performance computing (HPC) powered by the cloud
Whitepaper

Understanding the hidden value of quality

Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development.
Webinar

From Lead Optimization to Drug Candidate Triage: A Data-Driven Approach to Drug Discovery

Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies.
Whitepaper

4 ways to cut through the clutter and reach chronic disease patients

Learn how to help patients with chronic diseases access tailored condition and treatment insights in an environment where they are often inundated with one-size-fits-all messaging that doesn’t align with their individual healthcare journey.
Research

Creating a State-of-the-Art Integrated Digital Library Ecosystem

Daiichi Sankyo wanted to create a “single source of truth, the very first place you should go” for content access and rights information. How did they replace five tools with just one?
Whitepaper

Discover seven metaverse use cases for life sciences sales and marketing

From uncertainty to opportunity – Use cases for life sciences organizations to tap into the power of the metaverse and generative AI
Whitepaper

Ensuring a Reliable Biopharmaceutical Supply in the EU

Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk.
Whitepaper

Biology Informatics Solutions Brochure

From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types.
 

Industry Events

 

Upcoming Fierce Events

14-15
Nov
Free Virtual Event
14-16
Nov
London, UK
5
Dec
Edison Ballroom, New York City
9-10
Jan
San Francisco, CA
16-18
Jan
Virtual Event

View all events